Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Dedifferentiated chondrosarcomas are a rare and aggressive subtype of chondrosarcoma with a bimorphic pattern on histopathology. Rib is a rare site of dedifferentiated chondrosarcoma. Diagnosis of this subtype preoperatively can be challenging. Treatment options for dedifferentiated chondrosarcoma are limited because they are chemoresistant, and therefore adequate surgery forms the main stay of treatment. We present our experience with a dedifferentiated chondrosarcoma of the rib, and discuss the management of this rare entity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0218492314522253 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anti-PD-1 antibody plus anlotinib vs. anlotinib alone in patients with refractory chondrosarcoma: A multicenter, non-randomized phase 2 FLAIL-C trial.
Med
August 2025
Orthopaedic Oncology Services, Department of Orthopaedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China; Clinical Research Center of Motor System Disease of Zhejiang Province, Hangzhou 310009, China. Electronic address:
Background: There is no standard systemic therapy for unresectable chondrosarcoma. The purpose of this study is to explore the efficacy of combination therapy with an anti-PD-1 antibody and anlotinib in patients with advanced chondrosarcoma.
Methods: Patients with dedifferentiated or high-grade conventional chondrosarcoma were eligible.
Dedifferentiated adamantinoma of long bones: a case report and literature review.
Front Oncol
August 2025
Department of Pathology, the Hebei Medical University Third Hospital, Hebei, Shijiazhuang, China.
We present a rare case of dedifferentiated adamantinoma. The 48-year-old male patient was initially diagnosed with classic adamantinoma in the right fibula and underwent curettage. Two years postoperatively, the patient presented with progressive swelling and pain in the same region.
View Article and Find Full Text PDFCapacity of Understanding the Future Approaches in Cancer Treatment by Multiple Models of Artificial Intelligence.
J Cancer Educ
August 2025
Department of Orthopedic Surgery and BME, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Artificial intelligence (AI) has emerged as a popular tool in education for disease treatment, not only for patients but also for physicians and scientists. We aimed to explore the educational values of different AI models in future disease treatment by providing them with real-world obstacles in cancer treatment for the most serious types of breast cancer and chondrosarcoma. We first asked seven large AI models to predict the future treatment approaches that would lead to a better outcome for triple-negative breast cancer (TNBC) and dedifferentiated chondrosarcoma (DDCS).
View Article and Find Full Text PDFPurpose: Patients with metastatic chondrosarcoma at presentation have a poor prognosis. Owing to the lack of sensitivity to chemotherapy and radiotherapy, surgical resection is the mainstay of treatment of localized chondrosarcoma. The aim of this study was to investigate whether surgical resection of the primary site was associated with improved survival in patients with metastatic chondrosarcoma at presentation.
View Article and Find Full Text PDFIncidence, risk factors, and prognostic impact of regional lymph node metastasis in bone sarcoma: a population-based cohort study.
Jpn J Clin Oncol
September 2025
Department of Orthopaedic Surgery, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Background: This study aimed to investigate the risk factors and prognostic impact of regional lymph node metastasis (RLNM) in patients with bone sarcoma.
Methods: This retrospective study analyzed data from a Japanese registry of patients with bone sarcoma (2006-19). Disease-specific overall survival was estimated using the Kaplan-Meier method.